Hematology
3 drugs are in development for Hemophilia B.
- Companies
- 2
- Clinical trials
- 15
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Hemophilia B pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| alprolix | Bioverativ Inc. (BIVV) |
Preclinical(2)
| Drug | Company |
|---|---|
| dtx101 | Dimension Therapeutics, Inc. (DMTX) |
| dtx501 | Dimension Therapeutics, Inc. (DMTX) |
About this indication
Hemophilia B context
Hematology·MeSH: Hemophilia B (D002836)
Also known as: Deficiencies, F9, Deficiencies, Factor IX, Deficiency, F9, Deficiency, Factor IX, Disease, Christmas, Haemophilia B, Haemophilia Bs, Hemophilia Bs (M), Plasma Thromboplastin Component Deficiency
Prevalence
3.0 / 100K
Incidence
4.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Hemophilia B?
BioSniper tracks 3 drugs in development for Hemophilia B across 2 companies.
How many clinical trials target Hemophilia B?
There are 15 clinical trials targeting Hemophilia B tracked by BioSniper.
What is the prevalence of Hemophilia B?
The estimated prevalence of Hemophilia B is approximately 3.0 per 100,000 population.